INDEX

Volume 33 **1978**

A

A Cosmetic Legal Update. June, p. 252.

A New Prescription for Drug Law. March, p. 157.

A System for Assessing the Safety of the Components of Food. Aug., p. 383.

Administrative Hearings
Judicial Review Provisions of the Medical Device Amendments of 1976. Sept., p. 438.

Advertising
Advertising and The First Amendment. Jan., p. 12.
Comparison-Advertising Laws: An International Survey. Dec., p. 747.
FDA Inspections and Restricted Devices. July, p. 331.
Regulation of Food Labeling and Advertising by the Food and Drug Administration. Jan., p. 4.
The Defense of a False Advertising Case. Feb., p. 48.

Advertising and The First Amendment. Jan., p. 12.

Advisory Opinions
Federal Regulation of Cosmetics: An Overview. May, p. 231.

Agricultural Products
Regulatory Approaches to Food Composition. May, p. 220.

Allera, Edward J.
An Overview of How the FDA Regulates Carcinogens Under the Federal Food, Drug and Cosmetic Act. Feb., p. 59.
Ecumenicism and Efficiency—Future Issues in the Area of Food Regulation. Dec., p. 734.
FDA's Combination Animal Drug Policy—Is It Feasible? Or Should Elsie be the Only One Getting Milked? June, p. 167.

An Overview of How the FDA Regulates Carcinogens Under the Federal Food, Drug and Cosmetic Act. Feb., p. 59.

An Overview of the Meat and Poultry Inspection Program. Feb., p. 44.

Animal Drugs
FDA's Combination Animal Drug Policy—Is It Feasible? Or Should Elsie be the Only One Getting Milked? June, p. 267.
Freedom of Information—Animal Drug Regulations. June, p. 274.

B

Barmak, Mark E.—State Legislative Impact on the Drug Industry. Nov., p. 641.

The Basis and Purpose of Government Regulation of Adulteration and Misbranding of Food. Oct., p. 505.

Becton-Dickinson
Establishment Inspections: The Risk of Refusal. Nov., p. 680.
FDA Inspection and Restricted Devices. July, p. 331.

Berdick, Murray, Ph.D.—Cosmetic Industry Initiatives. May, p. 239.

Berry, Victor H., D.V.M.—An Overview of the Meat and Poultry Inspection Program. Feb., p. 44.

Biological Variability
FDA's Bio-Research Monitoring Program. April, p. 190.

Boddewyn, J. J.—Comparison-Advertising Laws: An International Survey. Dec., p. 747.

INDEX

Volume 33 **1978**

A

A Cosmetic Legal Update. June, p. 252.

A New Prescription for Drug Law. March, p. 157.

A System for Assessing the Safety of the Components of Food. Aug., p. 383.

Administrative Hearings
Judicial Review Provisions of the Medical Device Amendments of 1976. Sept., p. 438.

Advertising
Advertising and The First Amendment. Jan., p. 12.
Comparison-Advertising Laws: An International Survey. Dec., p. 747.
FDA Inspections and Restricted Devices. July, p. 331.
Regulation of Food Labeling and Advertising by the Food and Drug Administration. Jan., p. 4.
The Defense of a False Advertising Case. Feb., p. 48.

Advertising and The First Amendment. Jan., p. 12.

Advisory Opinions
Federal Regulation of Cosmetics: An Overview. May, p. 231.

Agricultural Products
Regulatory Approaches to Food Composition. May, p. 220.

Allera, Edward J.
An Overview of How the FDA Regulates Carcinogens Under the Federal Food, Drug and Cosmetic Act. Feb., p. 59.
Ecumenicism and Efficiency—Future Issues in the Area of Food Regulation. Dec., p. 734.
FDA's Combination Animal Drug Policy—Is It Feasible? Or Should Elsie be the Only One Getting Milked? June, p. 167.

An Overview of How the FDA Regulates Carcinogens Under the Federal Food, Drug and Cosmetic Act. Feb., p. 59.

An Overview of the Meat and Poultry Inspection Program. Feb., p. 44.

Animal Drugs
FDA's Combination Animal Drug Policy—Is It Feasible? Or Should Elsie be the Only One Getting Milked? June, p. 267.
Freedom of Information—Animal Drug Regulations. June, p. 274.

B

Barmak, Mark E.—State Legislative Impact on the Drug Industry. Nov., p. 641.

The Basis and Purpose of Government Regulation of Adulteration and Misbranding of Food. Oct., p. 505.

Becton-Dickinson
Establishment Inspections: The Risk of Refusal. Nov., p. 680.
FDA Inspection and Restricted Devices. July, p. 331.

Berdick, Murray, Ph.D.—Cosmetic Industry Initiatives. May, p. 239.

Berry, Victor H., D.V.M.—An Overview of the Meat and Poultry Inspection Program. Feb., p. 44.

Biological Variability
FDA's Bio-Research Monitoring Program. April, p. 190.

Boddewyn, J. J.—Comparison-Advertising Laws: An International Survey. Dec., p. 747.

Bozeman, Marc H.
Case Note—*U. S. v. General Foods Corporation, et al.* Aug., p. 424.
Recalls—On Making the Best of a Bad Thing. July, p. 342.

Brisson, Ernest L.—FDA's Bio-Research Monitoring Program. April, p. 190.

The Bureau of Biologics; What It Is and What It Does. April, p. 198.

C

Carcinogens
An Overview of How the FDA Regulates Carcinogens Under the Federal Food, Drug, and Cosmetic Act. Feb., p. 59.
Public Policy Issues in Regulating Carcinogens in Food. Oct., p. 541.
Unresolved Issues in the Conflict Between Individual Freedom and Government Regulation of Food Safety. Oct., p. 558.

Case Note—*Rutherford v. United States,* Aug., p. 428.

Case Note—*U. S. v. General Foods Corporation, et al.* Aug., p. 424.

Clausi, A. S.—Coping With Issues of Food Safety. Aug., p. 372.

Coal-Tar Derivatives
An Overview of How the FDA Regulates Carcinogens Under the Federal Food, Drug and Cosmetic Act. Feb., p. 59.

Coal-Tar Hair Dyes
A Cosmetic Legal Update. June, p. 252.

Codex Alimentarius Commission
Food Composition Regulation and Codex Standards. March, p. 145.
International Food Standards and National Laws. June, p. 281.
Reception of International Food Standards in National Laws. June, p. 292.

Color Additives
Regulatory Update on Cosmetics. July, p. 322.

Comments on the Proposed Drug Regulation Reform Act of 1978. Nov., p. 664.

Commerce Clause
What Hath *Rath* Wrought? Federal Preemption in Food Labeling. Jan., p. 28.

Commercial Speech
Advertising and The First Amendment. Jan., p. 12.

Common or Usual Names
Regulation of Food Labeling and Advertising by the Food and Drug Administration. Jan., p. 4.

Comparison-Advertising Laws: An International Survey. Dec., p. 747.

Condon, William J.—Product Liability —1977. July, p. 312.

Consent Decrees
Seizures and Injunctions: Their Role in FDA's Enforcement Program. Nov., p. 596.

Constitutional Rights
Education and Promotion—Where is the Line? June, p. 260.

Conway, Thomas G.—Remarks. Jan., p. 22.

Cooper, Richard M.—The Role of Regulatory Agencies in Risk-Benefit Decision-Making. Dec., p. 755.

Coping With Issues of Food Safety. Aug., p. 372.

Corrective Advertising
What Is Happening to OTC Drugs? April, p. 203.

Cosmetic Industry Initiatives. May, p. 239.

Cosmetic Ingredient Review
Cosmetic Industry Initiatives. May, p. 239.

Cosmetics
An Overview of How the FDA Regulates Carcinogens Under the Federal Food, Drug and Cosmetic Act. Feb., p. 59.
Cosmetic Industry Initiatives. May, p. 239.
Federal Regulation of Cosmetics: An Overview. May, p. 231.
Regulatory Update on Cosmetics. July, p. 322.
The Effect of the FDA's OTC Drug Review Program on the Cosmetic Industry. Feb., p. 78.

Credentialing
Drug Marketing: Non-Federal Regulation. Nov., p. 622.
Criminal Prosecutions, Inspections and Section 305 Hearings. July, p. 360.
Crout, J. Richard, M. D.—The Nature of Regulatory Choices. Aug., p. 413.
Cutler, Harris O.—Regulatory Update on Cosmetics. July, p. 322.

D

The Defense of a False Advertising Case. Feb., p. 48.
Delaney Clause
A New Prescription for Drug Law. March, p. 157.
An Overview of How The FDA Regulates Carcinogens Under the Federal Food, Drug and Cosmetic Act. Feb., p. 59.
Judicial Review Provisions of the Medical Device Amendments of 1976. Sept., p. 438.
Public Policy Issues in Regulating Carcinogens in Food. Oct., p. 541.
The Delaney Myths. Aug., p. 396.
Delville, Robert—Reception of International Food Standards in National Legislation. June, p. 292.
Detention and Seizure of Imports by the Food and Drug Administration. Dec., p. 726.
DESI Program
The Variegated Marketer: Playing Linnaeus to a Statute. Nov., p. 607.
Devices
Marketing a New Drug Product. Nov., p. 634.
Diabetics
The New and Reduced Calorie Food Regulations. Jan., p. 35.
Dispensing Information
Drug Marketing: Non-Federal Regulation. Nov., p. 622.
Dorsen Panel Report
Regulation in the Public Interest. April, p. 164.
Drug Marketing
Drug Marketing: Non-Federal Regulation. Nov., p. 622.
Drug Marketing Today: A Consumer View. Nov., p. 614.
Marketing a New Drug Product. Nov., p. 634.
Phase IV Testing—Overview and Summary of Pending Legislative Proposals. April, p. 173.
Drug Marketing: Non-Federal Regulation. Nov., p. 622.
Drug Marketing Today: A Consumer View. Nov., p. 614.
Drug Regulation Reform Act
Comments on the Proposed Drug Regulation Reform Act of 1978. Nov., p. 664.
"First the Good News: You're Not Going to Jail. . .". Sept., p. 482.
The Inspectional Process: A Statutory Overview. Dec., p. 697.
Phase IV Testing—Overview and Summary of Pending Legislative Proposals. April, p. 173.
The Role of Regulatory Agencies in Risk-Benefit Decision-Making. Dec., p. 755.
State Legislation and the Regulation of OTC Drugs. Nov., p. 650.
Technical Problems with the Drug Regulation Reform Act of 1978. Nov., p. 674.

E

Ecumenicism and Efficiency—Future Issues in the Area of Food Regulation. Dec., p. 734.
Education and Promotion—Where Is the Line? June, p. 260.
The Effect of the FDA's OTC Drug Review Program on the Cosmetic Industry. Feb., p. 78.
Elman, Philip—Advertising and The First Amendment. Jan., p. 12.
Establishment Inspections: The Risk of Refusal. Nov., p. 680.
European Economic Community
Comparison-Advertising Laws: An International Survey. Dec., p. 747.
International Food Standards and National Laws. June, p. 281.
Reception of International Food Standards in National Legislation. June, p. 292.

Exclusionary Rule
The Defense of a False Advertising Case. Feb., p. 48.

F

FDA Inspection and Restricted Devices. July, p. 331.

FDA Inspectional Authority—Is There an Outer Limit? Dec., p. 710.

FDA Inspectional Records and Freedom of Information. Dec., p. 692.

FDA's Bio-Research Monitoring Program. April, p. 190.

FDA's Combination Animal Drug Policy —Is It Feasible? Or Should Elsie be the Only One Getting Milked? June, p. 267.

Federal Embargoes
"First the Good News: You're Not Going to Jail. . .". Sept., p. 482.

Federal Preemption
What Hath *Rath* Wrought? Federal Preemption in Food Labeling. Jan., p. 28.
Ecumenicism and Efficiency—Future Issues in the Area of Food Regulation. Dec., p. 734.

Federal Regulation of Cosmetics: An Overview. May, p. 231.

Finkel, Marion J., M. D.—Phase IV Testing: FDA Viewpoint and Expectations. April, p. 181.

"First the Good News: You're Not Going to Jail. . .". Sept., p. 482.

Food Additive Safety Review
FDA's Bio-Research Monitoring Program. April, p. 190.

Food Additives
An Overview of How the FDA Regulates Carcinogens Under The Federal Food, Drug and Cosmetic Act. Feb., p. 59.
Marketing a New Drug Product. Nov., p. 634.
Remarks. March, p. 135.
The Delaney Myths. Aug., p. 396.

Food Composition Regulation and Codex Standards. March, p. 145.

Food Labeling
Regulation of Food Labeling and Advertising by the Food and Drug Administration. Jan., p. 4.
Remarks. Jan., p. 22.
The Food Safety Council—One Small Step Toward a Better Way. Aug., p. 376.
What Hath *Rath* Wrought? Federal Preemption in Food Labeling. Jan., p. 28.

Food Regulation
The Basis and Purpose of Government Regulation of Adulteration and Misbranding of Food. Oct., p. 505.

Food Safety
A System for Assessing the Safety of the Components of Food. Aug., p. 383.
Coping With Issues of Food Safety. Aug., p. 372.
Public Policy Issues in Regulating Carcinogens in Food. Oct., p. 541.
The Basis and Purpose of Government Regulation of Adulteration and Misbranding of Food. Oct., p. 505.
The Food Safety Council—One Small Step Toward a Better Way. Aug., p. 376.
The Role of Academic and Government Research in Food Technology. Aug., p. 405.
The Role of Regulatory Agencies in Risk-Benefit Decision-Making. Dec., p. 755.
Unresolved Issues in the Conflict Between Individual Freedom and Government Control of Food Safety. Oct., p. 558.
We Can Make Better Decisions. Aug., p. 391.

The Food Safety Council—One Small Step Toward a Better Way. Aug., p. 376.

Food Standards and the Consumer. March, p. 151.

Food Supplements
Regulatory Approaches to Food Composition. May, p. 220.

Forbes, Allan L., M. D.—Regulatory Approaches to Food Composition. May, p. 220.

Freedom of Information
Criminal Prosecutions, Inspections and Section 305 Hearings. July, p. 360.
FDA Inspectional Records and Freedom of Information. Dec., p. 692.
Freedom of Information—Animal Drug Regulations. June, p. 274.
Legal Issues in Food Establishment Inspections. March, p. 121.
Trade Secret Information in NADA's. July, p. 308.
Freedom of Information—Animal Drug Regulations. June, p. 274.
Future Issues
Ecumenicism and Efficiency—Future Issues in the Area of Food Regulation. Dec., p. 734.

G

Generic Drugs
Generic Drugs—Tomorrow's Market. Sept., p. 488.
Generic Drugs—Tomorrow's Market. Sept., p. 488.
Generic Monographs
Comments on the Proposed Drug Regulation Reform Act of 1978. Nov., p. 664.
Gerard, Alain—International Food Standards and National Laws. June, p. 281.
Gilhooley, Margaret—Federal Regulation of Cosmetics: An Overview. May, p. 231.
Good Laboratory Practice Regulations
FDA's Bio-Research Monitoring Program. April, p. 190.
Good Manufacturing Practices
A Cosmetic Legal Update. June, p. 252.
Cosmetic Industry Initiatives. May, p. 239.
"First the Good News: You're Not Going to Jail. . .". Sept., p. 482.
Judicial Review Provisions of the Medical Device Amendments of 1976. Sept., p. 438.
Legal Issues in Food Establishment Inspections. March, p. 121.
75 Years Compliance With Biological Product Regulations. May, p. 225.
GRAS Substances
An Overview of How the FDA Regulates Carcinogens Under the Federal Food, Drug, and Cosmetic Act. Feb., p. 59.
Drug Marketing Today: A Consumer View. Nov., p. 614.
The Delaney Myths. Aug., p. 396.

H

Haddad, William F.—Generic Drugs—Tomorrow's Market. Sept., p. 488.
Harris Poll
Remarks. March, p. 135.
Hearings
FDA Inspectional Records and Freedom of Information. Dec., p. 692.
Henteleff, Thomas O.
A Cosmetic Legal Update. June, p. 252.
The Delaney Myths. Aug., p. 396.
Hopper, Paul F., Ph. D.—We Can Make Better Decisions. Aug., p. 391.
How Kraft Behaves During an FDA Inspection. March, p. 116.
How to Handle an FDA Inspection. March, p. 101.
How to Handle an FDA Inspection —The Investigator's View. March, p. 109.
Hutt, Peter Barton
Public Policy Issues in Regulating Carcinogens in Food. Oct., p. 541.
The Basis and Purpose of Government Regulation of Adulteration and Misbranding of Food. Oct., p. 505.
Unresolved Issues in the Conflict Between Individual Freedom and Government Control of Food Safety. Oct., p. 558.
Hyman, Paul, M.—What Is Happening to OTC Drugs? April, p. 203.

I

Ice Cream Standards
Food Standards and the Consmuer. March, p. 151.
The Newest Regulatory Agency in Washington. Feb., p. 86.
Indirect Additives
The Newest Regulatory Agency in Washington. Feb., p. 86.

Informal Hearings
Criminal Prosecutions, Inspections and Section 305 Hearings. July, p. 360.

Informed Patient Consent
Phase IV Testing—Overview and Summary of Pending Legislative Proposals. April, p. 173.

Inspectional Photography
How to Handle an FDA Inspection. March, p. 101.
How to Handle an FDA Inspection—The Investigator's View. March, p. 109.
Legal Issues in Food Establishment Inspections. March, p. 121.
The Inspectional Process: A Statutory Overview. Dec., p. 697.

Inspections
Criminal Prosecutions, Inspections and Section 305 Hearings. July, p. 360.
Establishment Inspections: The Risk of Refusal. Nov., p. 680.
FDA Inspectional Authority—Is There an Outer Limit? Dec., p. 710.
FDA Inspectional Records and Freedom of Information. Dec., p. 692.
FDA Inspections and Restricted Devices. July, p. 331.
How Kraft Behaves During an FDA Inspection. March, p. 116.
How to Handle an FDA Inspection. March, p. 101.
How to Handle an FDA Inspection—The Investigator's View. March, p. 109.
The Inspectional Process: A Statutory Overview. Dec., p. 697.
Legal Issues in Food Establishment Inspections. March, p. 121.
Seizures and Injunctions: Their Role in FDA's Enforcement Program. Nov., p. 596.

Inspector Operations Manual
Legal Issues in Food Establishment Inspections. March, p. 121.
FDA Inspection and Restricted Devices. July, p. 331.
FDA Inspectional Authority—Is There an Outer Limit? Dec., p. 710.

International Food Standards
International Food Standards and National Laws. June, p. 281.
Reception of International Food Standards in National Legislation. June, p. 292.

International Food Standards and National Laws. June, p. 281.

***In Vitro* Testing**
Unresolved Issues in the Conflict Between Individual Freedom and Government Control of Food Safety. Oct., p. 558.

J

Jackson, William L.—FDA Inspectional Records and Freedom of Information. Dec., p. 692.

Johnstone, James M.—Phase IV Testing—Overview and Summary of Pending Legislative Proposals. April, p. 173.

Judicial Review
Judicial Review Provisions of the Medical Device Amendments of 1976. Sept., p. 438.

Judicial Review Provisions of the Medical Device Amendments of 1976. Sept., p. 438.

K

Karel, Marcus—The Role of Academic and Government Research in Food Technology. Aug., p. 405.

Kelleher, William A.—FDA Inspection and Restricted Devices. July, p. 331.

Kimbrell, Eddie F.—Food Composition Regulation and Codex Standards. March, p. 145.

Kingham, Richard F.—Comments on the Drug Regulation Reform Act of 1978. Nov., p. 664.

Kosher Foods
Remarks. Jan., p. 22.

L

Labeling
State Legislation and the Regulation of OTC Drugs. Nov., p. 650.
State Legislative Impact on the Drug Industry. Nov., p. 641.

Technical Problems With the Drug Regulation Reform Act of 1978. Nov., p. 674.
The Basis and Purpose of Government Regulation of Adulteration and Misbranding of Food. Oct., p. 505.
The Effect of the FDA's OTC Drug Review Program on the Cosmetic Industry. Feb., p. 78.
The Newest Regulatory Agency in Washington. Feb., p. 86.
What Is Happening to OTC Drugs? April, p. 203.

Laetrile
The Basis and Purpose of Government Regulation of Adulteration and Misbranding of Food. Oct., p. 505.
The Nature of Regulatory Choices. Aug., p. 413.
The Newest Regulatory Agency in Washington. Feb., p. 86.

Lambert, Eugene I.—The Variegated Marketer: Playing Linnaeus to a Statute. Nov., p. 607.

Legal Issues in Food Establishment Inspections. March, p. 121.

Licenses
"First the Good News: You're Not Going to Jail. . .". Sept., p. 482.

Linderman. Terrence G.—Freedom of Information—Animal Drug Regulations. June, p. 174.

Lushbough, Channing H., Ph. D.—How Kraft Behaves During an FDA Inspection. March, p. 116.

M

Magnuson-Moss Amendments
The Defense of a False Advertising Case. Feb., p. 48.

Manelli, Daniel J.—State Legislation and the Regulation of OTC Drugs. Nov., p. 650.

Manufacturer Identification
State Legislation and the Regulation of OTC Drugs. Nov., p. 650.
State Legislative Impact on the Drug Industry. Nov., p. 641.

Mark, Neil L.—Case Note—Rutherford v. United States. Aug., p. 428.

Marketing a New Drug Product. Nov., p. 634.

Meat and Poultry Inspection
An Overview of the Meat and Poultry Inspection Program. Feb., p. 44.

Medical Communications
Education and Promotion—Where is the Line? June, p. 260.

Medical Device Amendments
Judicial Review Provisions of the Medical Device Amendments of 1976. Sept., p. 438.

Medical Devices
Recalls—On Making the Best of a Bad Thing. July, p. 342.

Monographs
Comments on the Proposed Drug Regulation Reform Act of 1978. Nov., p. 664.
"First the Good News: You're Not Going to Jail. . .". Sept., p. 482.
Technical Problems With the Drug Regulation Reform Act of 1978. Nov., p. 674.

Morlock, Frank J.—Judicial Review Provisions of the Medical Device Amendments of 1976. Sept., p. 438.

N

National Disease and Therapeutic Index
Phase IV Testing: FDA Viewpoint and Expectations. April, p. 181.

National Institute of Health
The Bureau of Biologics; What It is and What It Does. April, p. 198.

The Nature of Regulatory Choices. Aug., p. 413.

Neely, Alfred S.—FDA Inspectional Authority—Is There an Outer Limit? Dec., p. 710.

The New and Reduced Calorie Food Regulations. Jan., p. 35.

New Animal Drug Applications
Freedom of Information—Animal Drug Regulations. June, p. 274.

Trade Secret Information in NADA's. July, p. 308.

New Drug Applications
Drug Marketing Today: A Consumer View. Nov., p. 614.
Marketing a New Drug Product. Nov., p. 634.
Phase IV Testing—Overview and Summary of Pending Legislative Proposals. April, p. 173.
The Nature of Regulatory Choices. Aug., p. 413.

New York Drug List
State Legislative Impact on the Drug Industry. Nov., p. 641.

The Newest Regulatory Agency in Washington. Feb., p. 86.

Nitrosamines
Regulatory Update on Cosmetics. July, p. 322.

Nutrition
The Food Safety Council—One Small Step Toward a Better Way. Aug., p. 376.

Nutritional Labeling
Food Composition Regulation and Codex Standards. March, p. 145.
The New and Reduced Calorie Food Regulations. Jan., p. 35.

O

Office of Consumer Representation Remarks. March, p. 135.

O'Keefe, Daniel F. Jr.
Legal Issues in Food Establishment Inspections. March, p. 121.
Technical Problems With the Drug Regulation Reform Act of 1978. Nov., p. 674.

Orange Juice Amendments
Food Standards and the Consumer. March, p. 151.

O'Reilly, James T.—"First the Good News: You're Not Going to Jail. . .". Sept., p. 482.

OTC Drug Review
Federal Regulation of Cosmetics: An Overview. May, p. 231.
State Legislation and the Regulation of OTC Drugs. Nov., p. 650.
The Effect of the FDA's OTC Drug Review Program on the Cosmetic Industry. Feb., p. 78.
The Variegated Marketer: Playing Linnaeus to a Statute. Nov., p. 607.
What Is Happening to OTC Drugs? April, p. 203.

Ozone Depletion
A Cosmetic Legal Update. June, p. 252.

P

Parish, Peter S.—Regulation in the Public Interest. April, p. 164.

Peterson, Esther—Remarks. March, p. 135.

Phase IV Labeling
Phase IV Testing—Overview and Summary of Pending Legislative Proposals. April, p. 173.
Phase IV Testing: FDA Viewpoint and Expectations. April, p. 181.
Phase IV Testing—Overview and Summary of Pending Legislative Proposals. April, p. 173.

Phase IV Testing: FDA Viewpoint and Expectations. April, p. 181.

Phase IV Testing—Overview and Summary of Pending Legislative Proposals. April, p. 173.

Polio Vaccine
Product Liability—1977. July, p. 312.

Prescription Drugs
Drug Marketing: Non-Federal Regulation. Nov., p. 622.
Marketing a New Drug Product. Nov., p. 634.

Product Liability—1977. July, p. 312.

Public Health Service
The Bureau of Biologics; What It is and What It Does. April, p. 198.

Public Policy Issues in Regulating Carcinogens in Food. Oct., p. 541.

R

Recalls
Recalls—On Making the Best of a Bad Thing. July, p. 342.

Recalls—On Making the Best of a Bad Thing. July, p. 342.

Reception of International Food Standards in National Legislation. June, p. 292.

Regulation in the Public Interest. April, p. 164.
Regulation of Food Labeling and Advertising by the Food and Drug Administration. Jan., p. 4.
Regulatory Approaches to Food Composition. May, p. 220.
Regulatory Procedures Manual
Recalls—On Making the Best of a Bad Thing. July, p. 342.
Regulatory Update on Cosmetics. July, p. 322.
Remarks. Jan., p. 22.
Remarks. March, p. 135.
Research and Development
Regulation in the Public Interest. April, p. 164.
Retailer Liability
Product Liability—1977. July, p. 312.
Rogers, Paul G.—A New Prescription for Drug Law. March, p. 157.
The Role of Academic and Government Research in Food Technology. Aug., p. 405.
The Role of Regulatory Agencies in Risk-Benefit Decision-Making. Dec., p. 755.
Rothschild, Louis, Jr.—The Newest Regulatory Agency in Washington. Feb., p. 86.

S

Saccharin
Public Policy Issues in Regulating Carcinogens in Food. Oct., p. 541.
The Nature of Regulatory Choices. Aug., p. 413.
The Newest Regulatory Agency in Washington. Feb., p. 86.
Safir, Peter O.—Establishment Inspections: The Risk of Refusal. Nov., p. 680.
Schultz, William—Drug Marketing Today: A Consumer View. Nov., p. 614.
Seizures
Criminal Prosecutions, Inspections and Section 305 Hearings. July, p. 360.
Detention and Seizure of Imports by the Food and Drug Administration. Dec., p. 726.
Seizures and Injunctions
FDA Inspections and Restricted Devices. July, p. 331.
Legal Issues in Food Establishment Inspections. March, p. 121.
Seizures and Injunctions: Their Role in FDA's Enforcement Program. Nov., p. 596.
Seizures and Injunctions: Their Role in FDA's Enforcement Program. Nov., p. 596.
75 Years Compliance with Biological Product Regulations. May, p. 225.
Shupak, Richard A.—Inspectional Process: A Statutory Overview. Dec., p. 697.
Skinner, William J.—Drug Marketing: Non-Federal Regulation. Nov., p. 622.
Skitol, Robert A.—The Defense of a False Advertising Case. Feb., p. 48.
Smith, D. Joe, Jr.
Detention and Seizure of Imports by The Food and Drug Administration. Dec., p. 726.
What Hath *Rath* Wrought? Federal Preemption in Food Labeling. Jan., p. 28.
Spiller, Robert M.—How to Handle an FDA Inspection. March, p. 101.
State Legislation and the Regulation of OTC Drugs. Nov., p. 650.
State Legislative Impact on the Drug Industry. Nov., p. 641.
State Preemption
State Legislation and the Regulation of OTC Drugs. Nov., p. 650.
State Legislative Impact on the Drug Industry. Nov., p. 641.
Statute of Limitations
Product Liability—1977. July, p. 312.
Stephenson, Marilyn G.—The New and Reduced Calorie Food Regulations. Jan., p. 35.
Stribling, Jess H., Jr.—Regulation of Food Labeling and Advertising by the Food and Drug Administration. Jan., p. 4.

Substitution
Generic Drugs—Tomorow's Market. Sept., p. 488.
State Legislative Impact on the Drug Industry. Nov., p. 641.
Summary Judgements
Comments on the Proposed Drug Regulation Reform Act of 1978. Nov., p. 664.
The Variegated Marketer: Playing Linnaeus to a Statute. Nov., p. 607.
What Is Happening to OTC Drugs? April, p. 203.
Swanson, James W.—How to Handle an FDA Inspection—The Investigator's View. March, p. 109.

T

Taylor, Michael R.—Seizures and Injunctions: Their Role in FDA's Enforcement Program. Nov., p. 596.
Technical Problems With the Drug Regulation Reform Act of 1978. Nov., p. 674.
Tenney, Janet—Food Standards and the Consumer. March, p. 151.
Timm, Eugene A., Ph. D.—75 Years Compliance With Biological Product Regulations. May, p. 225.
Toxicity
A System for Assessing the Safety of the Components of Food. Aug., p. 383.
Trade Secret Information
Trade Secret Information in NADA's. July, p. 308.
Trade Secret Information in NADA's. July, p. 308.
Trade Secrets
Freedom of Information—Animal Drug Regulations. June, p. 274.
Turner, James S.—The Food Safety Council—One Small Step Toward a Better Way. Aug., p. 376.

U

Unresolved Issues in the Conflict Between Individual Freedom and Government Control of Food Safety. Oct., p. 558.

V

Van Houweling, C. D., D. V. M.—Trade Secret Information in NADA's. July, p. 308.
The Variegated Marketer: Playing Linnaeus to a Statute. Nov., p. 607.
Veterinary Medicine
FDA's Combination Animal Drug Policy—Is It Feasible? Or Should Elsie be the Only One Getting Milked? June, p. 167.
Victorin, Robert R.—Education and Promotion—Where is the Line? June, p. 260.

Y

Yingling, Gary L.—The Effect of the FDA's OTC Drug Review Program on the Cosmetic Industry. Feb., p. 78.
Youngs, Maynard L.—Marketing a New Drug Product. Nov., p. 634.

W

The Warenwet
Reception of International Food Standards in National Laws. June, p. 292.
Warrant
Establishment Inspections: The Risk of Refusal. Nov., p. 680.
FDA Inspections and Restricted Devices. July, p. 331.
How to Handle an FDA Inspection. March, p. 101.
Legal Issues in Food Establishment Inspections. March, p. 121.
We Can Make Better Decisions. Aug., p. 391.
What Hath *Rath* Wrought? Federal Preemption in Food Labeling. Jan., p. 28.
What Is Happening to OTC Drugs? April, p. 203.
Wilmoth, Robert—Criminal Prosecutions, Inspections and Section 305 Hearings. July, p. 360.
Wodicka, Virgil O., Ph.D.—A System for Assessing the Safety of the Components of Food. Aug., p. 383.